1560968-55-9 Usage
Uses
Used in Pharmaceutical Industry:
4-(3-(4-(cyclopentyl(amino)(phenyl)methyl)piperidin-1-yl)propoxy)benzonitrile is used as a small-molecule inhibitor for targeting specific protein-protein interactions in the treatment of acute leukemia. Its design closely mimics the natural interaction between menin and mixed lineage leukemia (MLL), making it a potential therapeutic agent for this type of cancer.
Used in Drug Delivery Systems:
In the field of drug delivery, 4-(3-(4-(cyclopentyl(amino)(phenyl)methyl)piperidin-1-yl)propoxy)benzonitrile can be utilized as a component in the development of novel drug carriers. Its unique chemical structure allows for the potential enhancement of drug delivery, bioavailability, and therapeutic outcomes when combined with various organic and metallic nanoparticles.
Used in Chemical Research:
4-(3-(4-(cyclopentyl(amino)(phenyl)methyl)piperidin-1-yl)propoxy)benzonitrile may also find applications in chemical research, particularly in the synthesis of new compounds and the study of their properties. Its complex structure and potential for interaction with other molecules make it an interesting candidate for further investigation and development in the field of chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 1560968-55-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,5,6,0,9,6 and 8 respectively; the second part has 2 digits, 5 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1560968-55:
(9*1)+(8*5)+(7*6)+(6*0)+(5*9)+(4*6)+(3*8)+(2*5)+(1*5)=199
199 % 10 = 9
So 1560968-55-9 is a valid CAS Registry Number.
1560968-55-9Relevant academic research and scientific papers
High-affinity small-molecule inhibitors of the menin-mixed lineage leukemia (MLL) interaction closely mimic a natural protein-protein interaction
He, Shihan,Senter, Timothy J.,Pollock, Jonathan,Han, Changho,Upadhyay, Sunil Kumar,Purohit, Trupta,Gogliotti, Rocco D.,Lindsley, Craig W.,Cierpicki, Tomasz,Stauffer, Shaun R.,Grembecka, Jolanta
, p. 1543 - 1556 (2014/03/21)
The protein-protein interaction (PPI) between menin and mixed lineage leukemia (MLL) plays a critical role in acute leukemias, and inhibition of this interaction represents a new potential therapeutic strategy for MLL leukemias. We report development of a novel class of small-molecule inhibitors of the menin-MLL interaction, the hydroxy- and aminomethylpiperidine compounds, which originated from HTS of ～288000 small molecules. We determined menin-inhibitor co-crystal structures and found that these compounds closely mimic all key interactions of MLL with menin. Extensive crystallography studies combined with structure-based design were applied for optimization of these compounds, resulting in MIV-6R, which inhibits the menin-MLL interaction with IC50 = 56 nM. Treatment with MIV-6 demonstrated strong and selective effects in MLL leukemia cells, validating specific mechanism of action. Our studies provide novel and attractive scaffold as a new potential therapeutic approach for MLL leukemias and demonstrate an example of PPI amenable to inhibition by small molecules.
